Literature DB >> 11535051

A comparative analysis of the immunological evolution of antibody 28B4.

J Yin1, E C Mundorff, P L Yang, K U Wendt, D Hanway, R C Stevens, P G Schultz.   

Abstract

In an effort to gain greater insight into the evolution of the redox active, catalytic antibody 28B4, the germline genes used by the mouse to generate this antibody were cloned and expressed, and the X-ray crystal structures of the unliganded and hapten-bound germline Fab of antibody 28B4 were determined. Comparison with the previously determined structures of the unliganded and hapten-bound affinity-matured Fab [Hsieh-Wilson, L. C., Schultz, P. G., and Stevens, R. C. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 5363] shows that the germline antibody binds the p-nitrophenyl ring of hapten 3 in an orientation significantly different from that seen in the affinity-matured antibody, whereas the phosphonate moiety is bound in a similar mode by both antibodies. The affinity-matured antibody 28B4 has more electrostatic and hydrophobic interactions with hapten 3 than the germline antibody and binds the hapten in a lock-and-key fashion. In contrast, significant conformational changes occur in the loops of CDR H3 and CDR L1 upon hapten binding to the germline antibody, consistent with the notion of structural plasticity in the germline antibody-combining site [Wedemayer, G. J., Patten, P. A., Wang, L. H., Schultz, P. G., and Stevens, R. C. (1997) Science 276, 1665]. The structural differences are reflected in the differential binding affinities of the germline Fab (K(d) = 25 microM) and 28B4 Fab (K(d) = 37 nM) to hapten 3. Nine replacement mutations were found to accumulate in the affinity-matured antibody 28B4 compared to its germline precursor. The effects of each mutation on the binding affinity of the antibody to hapten 3 were characterized in detail in the contexts of both the germline and the affinity-matured antibodies. One of the mutations, Asp95(H)Trp, leads to a change in the orientation of the bound hapten, and its presence is a prerequisite for other somatic mutations to enhance the binding affinity of the germline antibody for hapten 3. Thus, the germline antibody of 28B4 acquired functionally important mutations in a stepwise manner, which fits into a multicycle mutation, affinity selection, and clonal expansion model for germline antibody evolution. Two other antibodies, 20-1 and NZA6, with very different antigen specificities were found to be highly homologous to the germline antibody of 28B4, consistent with the notion that certain germline variable-region gene combinations can give rise to polyspecific hapten binding sites [Romesberg, F. E., Spiller, B., Schultz, P. G., and Stevens, R. C. (1998) Science 279, 1929]. The ultimate specificity of the polyspecific germline antibody appears to be defined by CDR H3 variability and subsequent somatic mutation. Insights into the evolution of antibody-combining sites provided by this and other structural studies are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535051     DOI: 10.1021/bi010536c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Structural evidence for substrate strain in antibody catalysis.

Authors:  Jun Yin; Scott E Andryski; Albert E Beuscher; Raymond C Stevens; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

2.  Protein dynamics and the immunological evolution of molecular recognition.

Authors:  Ralph Jimenez; Georgina Salazar; Jun Yin; Taiha Joo; Floyd E Romesberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-04       Impact factor: 11.205

3.  High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics.

Authors:  Stephen P Persaud; David L Donermeyer; K Scott Weber; David M Kranz; Paul M Allen
Journal:  Mol Immunol       Date:  2010-03-23       Impact factor: 4.407

4.  Probing a protein-protein interaction by in vitro evolution.

Authors:  George Thom; Alexis C Cockroft; Andrew G Buchanan; Cathy Joberty Candotti; E Suzanne Cohen; David Lowne; Phill Monk; Celia P Shorrock-Hart; Lutz Jermutus; Ralph R Minter
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

5.  Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment.

Authors:  Katarina S Midelfort; K Dane Wittrup
Journal:  Protein Sci       Date:  2006-02       Impact factor: 6.725

6.  Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics.

Authors:  Jörg Zimmermann; Erin L Oakman; Ian F Thorpe; Xinghua Shi; Paul Abbyad; Charles L Brooks; Steven G Boxer; Floyd E Romesberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

7.  Affinity-matured recombinant antibody fragments analyzed by single-molecule force spectroscopy.

Authors:  Julia Morfill; Kerstin Blank; Christian Zahnd; Beatrice Luginbühl; Ferdinand Kühner; Kay-E Gottschalk; Andreas Plückthun; Hermann E Gaub
Journal:  Biophys J       Date:  2007-08-03       Impact factor: 4.033

8.  Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function.

Authors:  K Scott Weber; David L Donermeyer; Paul M Allen; David M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

9.  Exploring the potential impact of an expanded genetic code on protein function.

Authors:  Han Xiao; Fariborz Nasertorabi; Sei-Hyun Choi; Gye Won Han; Sean A Reed; Raymond C Stevens; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

10.  Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.